000913394 000__ 04233cam\a2200577Ii\4500
000913394 001__ 913394
000913394 005__ 20230306150426.0
000913394 006__ m\\\\\o\\d\\\\\\\\
000913394 007__ cr\cn\nnnunnun
000913394 008__ 190828s2019\\\\sz\a\\\\ob\\\\001\0\eng\d
000913394 019__ $$a1111714316$$a1111980097$$a1115088752$$a1117707752
000913394 020__ $$a9783030163730$$q(electronic book)
000913394 020__ $$a3030163733$$q(electronic book)
000913394 020__ $$z9783030163716
000913394 020__ $$a3030163717
000913394 020__ $$a9783030163716
000913394 020__ $$a9783030163723
000913394 020__ $$a3030163725
000913394 0247_ $$a10.1007/978-3-030-16373-0$$2doi
000913394 0247_ $$a10.1007/978-3-030-16
000913394 035__ $$aSP(OCoLC)on1114290809
000913394 035__ $$aSP(OCoLC)1114290809$$z(OCoLC)1111714316$$z(OCoLC)1111980097$$z(OCoLC)1115088752$$z(OCoLC)1117707752
000913394 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dOCLCO$$dEBLCP$$dNOC$$dYDX$$dVT2$$dUPM$$dLQU$$dUKMGB
000913394 049__ $$aISEA
000913394 050_4 $$aRM267$$b.P65 2019eb
000913394 08204 $$a615.7/922$$223
000913394 24500 $$aPolymyxin antibiotics :$$bfrom laboratory bench to bedside /$$cJian Li, Roger L. Nation, Keith S. Kaye, editors.
000913394 264_1 $$aCham :$$bSpringer,$$c[2019]
000913394 264_4 $$c©2019
000913394 300__ $$a1 online resource :$$billustrations.
000913394 336__ $$atext$$btxt$$2rdacontent
000913394 337__ $$acomputer$$bc$$2rdamedia
000913394 338__ $$aonline resource$$bcr$$2rdacarrier
000913394 347__ $$atext file$$bPDF$$2rda
000913394 4901_ $$aAdvances in experimental medicine and biology,$$x0065-2598 ;$$vvolume 1145
000913394 504__ $$aIncludes bibliographical references and index.
000913394 5050_ $$aOverview -- Multidrug resistant Gram-negative pathogens: the urgent need for 'old' polymyxins -- Discovery, antibacterial spectrum and chemistry -- Mechanisms of antibacterial activity -- Mechanisms of resistance -- Bioanalysis and stability of polymyxins -- In vitro pharmacodynamics and PK/PD in animals -- Antibacterial susceptibility breakpoints -- Labeling of parenteral products of colistin methanesulfonate -- Meta-analysis of polymyxin use in patients -- Clinical use of colistin -- Clinical use of polymyxin B -- Pharmacokinetics, pharmacodynamics, toxicodynamics and dosing recommendations -- Rational combinations with other antibiotics -- Toxicities in patients: management and mechanisms -- Antiendotoxin effect -- Discovery of novel polymyxin-like antibiotics -- Conclusion.
000913394 506__ $$aAccess limited to authorized users.
000913394 520__ $$aIt is our wish that readers discover the importance of polymyxin structure in relation to the mechanisms of activity, resistance and toxicity. We emphasized that reliable analytic methods for polymyxins are critical when investigating their pharmacokinetics (PK) and pharmacodynamics (PD). The complicated dose definitions and different pharmacopoeial standards have already compromised the safe use of polymyxins in patients. Therefore, informed by the latest pharmacological information, scientifically-based dosing recommendations have been proposed for intravenous polymyxins. Considering the PK/PD limitations and potential development of resistance, polymyxin combinations are encouraged; however, the current literature has not shown definite microbiological benefits, possibly because most clinical studies to date overlooked key PK/PD principles. Nephrotoxicity is the major dose-limiting factor and it is imperative to elucidate the mechanisms and develop novel approaches to minimize polymyxin-associated toxicities. In addition, the anti-endotoxin effect of polymyxins supports their clinical use to treat Gram-negative sepsis. Fortunately, the discovery of new-generation polymyxins with wider therapeutic windows has benefited from the latest achievements in polymyxin research.
000913394 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed August 28, 2019).
000913394 650_0 $$aPolymyxin.
000913394 650_0 $$aAntibiotics.
000913394 7001_ $$aLi, Jian$$c(Pharmacologist),$$eeditor.
000913394 7001_ $$aNation, Roger L.,$$eeditor.
000913394 7001_ $$aKaye, Keith S.,$$eeditor.
000913394 77608 $$iPrint version:$$z9783030163716
000913394 830_0 $$aAdvances in experimental medicine and biology ;$$vv. 1145.
000913394 852__ $$bebk
000913394 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-030-16373-0$$zOnline Access$$91397441.1
000913394 909CO $$ooai:library.usi.edu:913394$$pGLOBAL_SET
000913394 980__ $$aEBOOK
000913394 980__ $$aBIB
000913394 982__ $$aEbook
000913394 983__ $$aOnline
000913394 994__ $$a92$$bISE